These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
568 related articles for article (PubMed ID: 30075736)
1. Combined pretreatment with Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736 [TBL] [Abstract][Full Text] [Related]
2. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases. Chung YL; Horng CF; Lee PI; Chen FL BMC Cancer; 2016 Mar; 16():179. PubMed ID: 26940959 [TBL] [Abstract][Full Text] [Related]
3. The prognostic value of FIGO staging defined by combining MRI and [ Raffa S; Lanfranchi F; Satragno C; Giannelli F; Marcenaro M; Coco A; Cena SE; Sofia L; Marini C; Mammoliti S; Levaggi A; Tagliafico AS; Sambuceti G; Barra S; Morbelli S; Belgioia L; Bauckneht M Curr Probl Cancer; 2023 Dec; 47(6):101007. PubMed ID: 37684197 [TBL] [Abstract][Full Text] [Related]
4. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422 [TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach. Draghini L; Costantini S; Vicenzi L; Italiani M; Loreti F; Trippa F; Arcidiacono F; Casale M; Mantello G; Maranzano E Radiol Med; 2019 Sep; 124(9):819-825. PubMed ID: 30904982 [TBL] [Abstract][Full Text] [Related]
8. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. Chen CC; Wang L; Lin JC; Jan JS J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262 [TBL] [Abstract][Full Text] [Related]
10. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer. Chang AJ; Richardson S; Grigsby PW; Schwarz JK Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):263-9. PubMed ID: 21167656 [TBL] [Abstract][Full Text] [Related]
12. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients. Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539 [TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer. Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479 [TBL] [Abstract][Full Text] [Related]
16. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer. Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967 [TBL] [Abstract][Full Text] [Related]
17. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282 [TBL] [Abstract][Full Text] [Related]
18. The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up. Lin SY; Tsai CS; Chang YC; Ng KK; Chang TC; Kao WH; Lai CH; Hong JH Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):577-85. PubMed ID: 25936817 [TBL] [Abstract][Full Text] [Related]